Login

Forgot password?
Sign up today and your first download is free.
REGISTER

Drug Pricing

May 29, 2018 | Daily News

Ahead of a key Senate committee hearing on President Donald Trump's plan to lower drug prices, Sen. Bill Cassidy (R-LA) released a white paper Tuesday (May 29) floating a number of ideas for lowering drug costs, including: passing on drug rebates to beneficiaries at the pharmacy counter, moving toward international reference pricing and cracking down on brand company efforts to block generic competition via abuses of Risk Evaluation and Mitigation Strategies (REMS).

May 25, 2018 | Daily News

The White House Office of Management and Budget on Thursday (May 24) began reviewing a final rule to again delay implementation of the 340B ceiling price and penalties rule.

May 25, 2018 | Daily News

A coalition of the nation's largest pharmacies are suing Allergan over what they alleged is a multiyear anticompetitive scheme to shield the company's dry eye drug Restasis from generic competition.

May 25, 2018 | Daily News

Spending on cancer drugs doubled in the past five years and is expected to double again in the next five years, but employers paid most of the increased costs.

May 24, 2018 | Daily News

The Congressional Budget Office believes the president's proposal to eliminate low-income beneficiaries' cost sharing for generic drugs would cost more than $18 billion dollars over 10 years, despite the fact that the White House Office of Management and Budget previously said the proposal would be nearly budget neutral.

May 24, 2018 | Daily News

HHS Secretary Alex Azar will testify June 12 on the president’s drug-price plan at a Senate health committee hearing, according to a committee release.

May 24, 2018 | Daily News

CMS might consider making plans factor drug rebates and pharmacy price concessions in Medicare Advantage and Part D bids to save Medicare beneficiaries money at the pharmacy counter, Washington Analysis states in a note to its clients.

May 24, 2018 | Daily News

Hospitals say there is no justification for the Health Resources and Services Administration's plan to delay for a fifth time implementing a rule on manufacturer penalties and ceiling price calculations in the 340B program, and they take issue with HRSA's claim that the delay won't hurt providers that may be overcharged by drug makers.

May 23, 2018 | Daily News

An Avalere analysis that asserts generic drug costs are rising for seniors in Part D due to plans putting generics on higher-cost tiers is “mostly founded on general speculation versus reliable fact,” a spokesperson for America’s Health Insurance Plans alleges.

May 23, 2018 | Daily News

CMS will soon request proposals from third parties to buy drugs on behalf of physicians, which is a defunct program HHS is reviving for the first time since it failed more than a decade ago.

May 22, 2018 | Daily News

Generic drug costs are rising for seniors in Part D, even though prices for the drugs remain flat, because plans are putting generics on higher formulary tiers, according to an Avalere analysis.

May 22, 2018 | Daily News

The House Rules Committee voted 7-4 Monday (May 21) evening to bring the Right to Try bill passed by the Senate last year directly to the House floor.

May 21, 2018 | Daily News

Many beneficiaries would pay much more for drugs if the administration moves doctor-administered Part B drugs into the Part D retail drug benefit, according to an Avalere analysis.

May 21, 2018 | Daily News

The Creating and Restoring Equal Access To Equivalent Samples Act (CREATES) Act is being considered as an offset for the opioid package moving through the House, lobbyists on both sides of the debate tell Inside Health Policy.

May 21, 2018 | Daily News

The U.S. Supreme Court Monday (May 21) declined to take up a case brought by a coalition of drug makers challenging consumers' standing to sue over money lost due to a product design that allegedly wastes a portion of that product.

May 18, 2018 | Daily News

CMS is writing another Part D rule, according to the unified agenda that outlines agency rulemaking plans, and Ross Margulies, an associate at Foley Hoag, expects that many of the president’s proposals to curb drug prices will be included in that rule.

May 17, 2018 | Daily News

CMS officially put drug plans on notice to stop using so-called gag orders that prohibit pharmacists from telling customers when it is more expensive to use insurance to buy drugs.

May 17, 2018 | Daily News

FDA's long-awaited list of brand drugs for which generics have sought the agency's help in obtaining the samples necessary for testing and approval confirms that Risk Evaluation and Mitigation Strategies are not the only tool used by brands to withhold samples.

May 17, 2018 | Daily News

CMS' Medicare Evidence Development & Coverage Advisory Committee will meet in August to consider a National Coverage Determination for chimeric antigen receptor (CAR)-T cell therapies after UnitedHealthcare requested such a determination to make sure there is a level playing field across Medicare for coverage of the expensive therapies.

May 17, 2018 | Daily News

Specialists with a big stake in Part B warn HHS that following through with the administration’s proposal to let Part D plans negotiate Part B drug prices would cause patients to face access restrictions in Part D that they don’t have to deal with in Part B.

Pages